To compare the continuous infusion and intermittent bolus injection administration protocols of doxorubicin (Dox) under the same cumulative dose (12 mg/kg), and establish a rat dilated cardiomyopathy model with improved survival, a total of 150 Sprague-Dawley (SD) rats were divided into three groups: a control group, administered with normal saline; a Dox 1 group, administration twice a week at 1 mg/kg; a Dox 2, administration once a week at 2 mg/kg. Mortality rates in the Dox 1 and Dox 2 groups were 22% and 48%, respectively (P<0.05). As shown by echocardiography, both Dox groups exhibited significant chamber dilatation and reduced cardiac function (all P<0.05 vs. control). Plasma brain natriuretic peptide and C-reactive protein concentrations were significantly increased (P<0.05) with both Dox regimens. The concentrations of Caspase-3 in myocardial tissues of rats significantly increased in both doxorubicin regimens. Myocardial metabolism imaging by histology and 18 F-fluoro-deoxyglucose-positron emission tomography ( 18 FDG-PET) both revealed decreased myocardial viability and necrosis, and even interstitial fibrosis, in left ventricles (LVs) in both Dox groups. Serum creatinine and aspartate aminotransferase concentrations were significantly higher in the Dox 2 model than in the Dox 1 model. Doxorubicin given at both regimens induced dilated cardiomyopathy, while its administration at lower doses with more frequent infusions reduced the mortality rate.
Introduction
Dilated cardiomyopathy (DCM) is a common side effect complication of cancer chemotherapy (Vejpongsa and Yeh, 2014) . Doxorubicin cardiotoxicity-induced DCM is characterized by chamber dilation and cardiac dysfunction, and prognosis is poor (Plana et al., 2014) . In cancer patients who survive for five years, approximately one in three patients die from cardiovascular disease. Attempts have been made to identify risk factors, lessen the use of toxic chemotherapeutic derivatives, or detect subclinical toxicity at earlier stages. Despite these attempts, there is no current consensus on the best approach to prevent cardiotoxicity from chemotherapeutic agents. Studies on new therapeutic modalities to prevent or reverse DCM have attracted much attention. These include the use of drugs or stem cells. Reliable experimental models for identifying new targets and testing new treatments are needed.
Doxorubicin is a common antineoplastic agent of the anthracycline group that was isolated from fungal cultures of Streptomyces peucetius var. (Carvalho et al., 2009) . Doxorubicin has a special affinity for the myocardium, and can induce DCM and congestive heart failure in cancer patients. Once congestive heart failure is diagnosed, the five year mortality rate becomes 50%. Reliable models of DCM using doxorubicin as the inducer are needed to better understand the mechanisms involved.
A DCM model was successfully established by intraperitoneally injecting rats with doxorubicin at a dose of 2 mg/kg once a week for six weeks (Turakhia et al., 2007) . A previous study also revealed that the mortality for this model is high (>50%). Delgado-Roche et al. (2014) induced DCM in a rat model with intraperitoneal doxorubicin at 1 mg/kg twice a week for six weeks. However, in their study, they did not evaluate survival as a major endpoint. Gava et al. (2013) induced DCM in a rabbit model with intraperitoneal doxorubicin at 1 mg/kg twice a week for six weeks. They found that doxorubicin induced pathology in the left and right ventricles, and concluded that administration at a dose of 1 mg/kg twice a week for six weeks is safe and sufficient to induce DCM in rabbits. The aim of the present study was to compare the standard administration protocol with the new administration protocol, which each had the same cumulative dose, but were divided into more frequent administrations, aiming to determine whether DCM would continue to occur, but with reduced mortality.
Materials and methods

Animal model and grouping
A total of 150 male Sprague-Dawley (SD) rats (eight weeks old, weighing 250-280 g) were randomized into three experimental groups, which consisted of 50 rats each: the control group, which received saline (0.9% (9 g/L) NaCl) by intraperitoneal injection; the Dox 1 group, which received doxorubicin by intraperitoneal injection at a dose of 1 mg/kg twice a week for six weeks; Dox 2 group, received doxorubicin by intraperitoneal injection at a dose of 2 mg/kg once a week for six weeks. Rats were treated for six weeks, and observed for two weeks. All animals were sacrificed eight weeks after the treatments were started, when the rats were four months of age.
Echocardiography
At four months of age, the rats were anesthetized with 10% chloral hydrate (3 ml/kg, intraperitoneal). Body hair was removed by shaving the chest region, and echocardiography was performed to assess cardiac morphology and function using a Philips CX50 ultrasound (Royal Dutch Philips Electronics Ltd., Amsterdam, Dutch) with a 12-MHz transducer. Images were gated to the electrocardiogram. A parasternal short axis view in the middle of the left ventricle (LV) at the level of papillary muscles was used for analysis. The LV end-systolic diameter (LVESD) and end-diastolic diameter (LVEDD) were measured. Fractional shortening (FS) was calculated as (LVEDD− LVESD)/LVEDD100%, and was calculated as a percentage (%). LV ejection fraction (LVEF) was calculated from the dimension values as (LVEDD 3 − LVESD 3 )/LVEDD 3 100%, and was calculated as a percentage (%). For each variable, images from three cardiac cycles were analyzed and averaged for each rat.
Plasma BNP and CRP, and serum CREA and AST
Twelve hours after echocardiography acquisition, uncoagulated blood was collected from the orbital venous plexus, anticoagulated with ethylene diamine tetraacetic acid (EDTA), and centrifuged at 13 000 r/min for 10 min. Serum was stored at −80 °C until further testing. Plasma brain natriuretic peptide (BNP) and C-reactive protein (CRP) concentrations were measured by enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions. Serum creatinine (CREA) and aspartate aminotransferase (AST) concentrations were measured by ELISA.
Caspase-3 mRNA analysis
Animals were euthanized with KCl (2 mol/L, intravenous). The heart was removed and rinsed with phosphate buffered saline (PBS), followed by the removal of the LV free wall. The excised myocardium was sliced into sections, and one section was snap-frozen at −80 C for mRNA evaluation by quantitative real-time polymerase chain reaction (PCR). The housekeeping gene β-actin was used as a reference gene. The gene sequences used are shown in Table 1 .
Histological analysis
Autopsy was performed on all animals that died before completing the study protocol. Surviving animals were euthanized with KCl (2 mol/L, intravenous). The heart was removed and rinsed with PBS, the septal wall myocardial tissue was fixed in 10% formalin and embedded in paraffin, and the sections (5 μm thick) were evaluated with hematoxylin and eosin (H & E) staining for microscopic observation. Animals that survived until the end of the study protocol were included in the histological analysis.
Myocardial metabolism imaging by 18 FDG-PET/computed tomography (CT)
Positron emission tomography (PET) has been used to monitor LV dilation in rats (Stegger et al., 2005; Handa et al., 2007) . The Siemens Inveon P120 PET scanner (Siemes, Inveon Dedicate, Germany) was used for PET imaging. The rats were fasted and water was withheld for 8 h before imaging to prevent interference from glucose during the imaging. After placing a catheter into the tail vein, rats were anesthetized with 10% chloral hydrate (3 ml/kg, intraperitoneal). The rats were positioned in the prone position within the PET scanner, and were kept warm with a heating pad. Core body temperature was maintained at 37 °C through the continuous monitoring of rectal temperature. After the intravenous administration of 2-deoxy-2-( 18 F)fluoro-D-glucose (FDG; (19±5) MBq), an electro-cardiogram (ECG)-gated emission recording followed throughout the interval 60-90 min after tracer injection, and was concluded by a 7-min transmission scan as previously described, which was obtained to assess myocardial viability (Gava et al., 2013) . Standard uptake value was defined using the following formula: intensity of the radioactivity of the region of interest (MBq/ml)/(radioactivity intensity of injected 18 FDG (MBq)×body weight (g)).
Statistical analysis
All data were processed with SPSS 21.0 software (Statistical Product and Service Solutions, Chicago, USA) and expressed as mean±standard deviation (SD). Kaplan-Meier analysis was performed to determine differences in survival rates. For parametric data, repeated measures analysis of variance (ANOVA) was used to compare the body weight in the four groups, and one-way ANOVA was used for the remaining continuous variables. When a statistically significant difference was observed among groups, a least significant difference test or Dunnett's test was performed. A P-value of <0.05 was considered statistically significant.
Results
General state of health
In Dox 1 and Dox 2 treated rats, body hair was ruffled and alopecia occurred. In addition, physical activity was reduced, and the rats ingested less food. Body weight was significantly reduced by the third week of injection, and the reduction in body weight was greater in the Dox 2 group than in the Dox 1 group (Fig. 1 ).
Mortality
There were no deaths in the saline-treated vehicle control group throughout the experiment, which was expected. Twenty-two percent (11/50) of the rats died in the Dox 1 group, while 48% (24/50) of rats 
Fig. 1 Changes of body weight in three groups
Values are presented as mean±standard deviation died in the Dox 2 group (P<0.001, by Kaplan-Meier analysis). Deaths were attributed to acute heart failure, serious gastrointestinal tract hemorrhage, or sudden cardiac death (Fig. 2) .
Echocardiography
Significant LV chamber dilatation was present in the Dox 1 and Dox 2 groups, compared to the control group, as evidenced by increased LVEDD and LVESD. As a result, there was a significant reduction in systolic function in the Dox 1 and Dox 2 groups, with decreased LVEF and FS (Table 2, Fig. 3 ).
Plasma BNP
Plasma BNP levels were significantly higher in the Dox 1 and Dox 2 groups, compared with the control group (Table 3 , Fig. 4 ; P<0.05 for both vs. the control group), which was consistent with the development of congestive heart failure.
Caspase-3 mRNA
Caspase-3 mRNA was significantly higher in the myocardium of rats in the Dox 1 and Dox 2 groups 
Histological analysis
Myocardial samples collected from rats in the control group revealed no histopathological changes, as expected. Myocardial samples obtained from the Dox 1 and Dox 2 groups revealed extensive cardiomyocyte vacuolization, degeneration and necrosis, interstitial edema, inflammatory cell infiltration, and replacement fibrosis (Fig. 6 ).
Myocardial metabolism imaging by 18 FDG-PET/CT
Myocardial metabolism imaging by 18 FDG-PET/ CT revealed a significant decrease in standard uptake values for FDG uptake, indicating reduced myocardial viability in both Dox 1 and Dox 2 groups (Table 5 , Fig. S1 ).
Serum CREA and AST, and plasma CRP
Serum CREA and AST, and plasma CRP levels were significantly higher in the Dox 1 and Dox 2 groups than in the control group. Serum CREA and AST, and plasma CRP levels were significantly higher in the Dox 2 group than the Dox 1 group ( 
Discussion
The goal of this study was to compare different administration times (once a week vs. twice a week) of doxorubicin, and to establish the rat DCM model that reduces animal usage. The major findings of this study revealed that the twice a week injection of 1 mg/kg for six weeks could generate LV dilation, reduce myocardial viability, and induce histopathological changes, which is consistent with DCM. Furthermore, these results indicate that doxorubicin can be used in rats at a concentration that induces DCM, while more than doubling the survival rate. This model would be useful for mechanistic studies in exploring causes and consequences of chemotherapyinduced cardiotoxicity.
Several other laboratories have used similar protocols to generate DCM models using doxorubicin injection. Yu et al. (2013) used a dose of 2.5 mg/kg of doxorubicin, which was intravenously administered twice a week for eight weeks. Other studies (Leontyev et al., 2013) used 2.5 mg/kg doses administered by intraperitoneal injection once a week for six weeks. Gu et al. (2012) induced DCM in a rat model using six equal doses of intraperitoneal doxorubicin, for a total dose of 15 mg/kg, which was administered for over two weeks. However, due to the leakage of doxorubicin from the intravenous injection, many of these protocols resulted in serious phlebitis, and even blocked blood vessels, which contributed to increased morbidity and mortality through mechanisms that are not clinically relevant. Although some researchers did not report the mortality rates in their studies, this study, as well as other studies, have reported high mortality that exceeded 50% for these protocols (Ishida et al., 2004; Baba et al., 2007; Iwata et al., 2013) . The author has previously reported a mortality rate of 54% when doxorubicin was injected intraperitoneally at doses of 2 mg/kg once a week in rats. Gu et al. (2012) induced DCM in a rabbit model with intraperitoneally administered doxorubicin (1 mg/kg, twice a week) for six weeks, and demonstrated that this method is safe and sufficient to induce DCM in rabbits. This is the reason the author used a similar protocol in rats. Doxorubicin is associated with a dose-dependent cardiotoxicity that can progress to heart failure, and the administration of doses over 1 mg/kg results in worse survival rates and classic signs of DCM (Hayward and Hydock, 2007) . In the present study, the investigators found that the administration of 1 mg/kg twice weekly in rats was safe and without high mortality rates, allowing reliable assessments at the end of the study. Similar to humans and other animal models, the toxic potential of doxorubicin in rats depends on the dose administered and the time course of administration (e.g. once or twice weekly). The high mortality in the Dox 2 group can be explained by the high toxicity potential of the drug in several organs. Nephrotoxicity, hepatotoxicity, and myelosuppression are noted as side effects in addition to its well-described cardiotoxicity effects, which limit the use of doxorubicin (Kalender et al., 2005; Bardi et al., 2007) . Our findings are consistent with previous research results. In the present study, plasma CREA and AST levels were significantly higher in rats administered weekly with doxorubicin at 2 mg/kg, indicating that nephrotoxicity and hepatotoxicity are more serious with a one-time dose. Anthracyclines significantly produce reactive free radicals that are capable of damaging cell membranes and DNA (Jones et al., 2006; Deng et al., 2009; Lu et al., 2009; Octavia et al., 2012) . Thus, this drug exerts time-and dose-dependent toxicity in several organs (El-Sayyad et al., 2009) .
CRP is an acute-phase protein, which has been found to be expressed in cardiomyocytes, endothelial cells, and microvascular endothelial cells in patients with DCM (Satoh et al., 2005) . CRP can induce myocardial injury by activating the complement system and inducing leukocyte chemotaxis (Zimmermann et al., 2009) . In DCM patients, elevated CRP was associated with inflammation and cardiac insufficiency (Mamamtavrishvili et al., 2008) . In the present study, plasma CRP levels were significantly higher in rats in the Dox 2 group, and had a high mortality.
The present study investigated the mechanism of the cardiomyocyte apoptosis involved in myocardial injury during the development of DCM (Kawano et al., 1994; Haider et al., 1995) . The cysteine aspartate protein (caspase) family includes functional proteases that regulate cell apoptosis, remodeling, and differentiation (Nicholson and Thornberry, 1997; Cryns and Yuan, 1998; Thornberry and Lazebnik, 1998) . Caspase-3 is a critical upstream protein that initiates the apoptosis pathway (Faleiro et al., 1997; Martins et al., 1997; Polverino and Patterson, 1997) . The activation of Caspase-3 occurs at early time points (1-24 h), as well as during the heart failure stage in the adriamycin (ADR)-induced cardiomyopathy model (Lou et al., 2005) . The expression of pro-apoptotic protein Caspase-3 was significantly higher in the ADR-induced DCM model (Liu et al., 2012) . The results of the current study are consistent with what others have reported, in which Caspase-3 mRNA was significantly elevated in the myocardium of rats treated with doxorubicin.
Echocardiography revealed that LV chamber dilatation, evidenced by enlarged LVEDD and LVESD, was translated to decreased fractional shortening and ejection fraction. These results were consistent with a previous report (Leontyev et al., 2013) . Histopathological analysis and 18 FDG-PET myocardial metabolism imaging confirmed the cardiotoxic effects of doxorubicin in rats. Cardiomyocyte damages, leading to necrosis, edema, inflammatory cell infiltration, and fibrosis, were similar in both models. Similarly, 18 FDG-PET myocardial metabolism imaging revealed decreased myocardial viability, which was consistent with the findings reported by another study (Brunner et al., 2012) . Similar to echocardiography, 18 FDG-PET imaging is a useful and minimally invasive evaluation method that can be used to detect pathological changes, offering the benefit of being useful for serial evaluations.
Conclusions
In conclusion, we compared two dosing regimens of doxorubicin in rats to determine a minimal protocol that can induce DCM, while improving survival. The administration of 1 mg/kg of doxorubicin twice a week for six weeks was found to be safe and sufficient for inducing DCM in rats.
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